Kyowa Kirin
Japan-based global specialty pharmaceutical company developing biologics for rare disease, oncology and immune-mediated conditions.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Achondroplasia
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaPhase 2 · Recruiting · Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of KK2430 in Participants With Hematologic NeoplasmsPhase 1 · Recruiting · Hematologic Neoplasms
Study of KK3910 in Healthy Volunteers and Patients With Essential HypertensionPhase 1 · Recruiting · Healthy Volunteers Essential Hypertension
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceNA · Recruiting · Mycosis Fungoides
A Study of KK2269 in Adult Participants With Solid TumorsPhase 1 · Recruiting · Advanced Solid Tumor
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/kyowa-kirin/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.